top of page

Bridging Biology, Technology, and Collaboration: The Path Forward for Mental Health Research

  • Writer: Gila Tolub
    Gila Tolub
  • 4 days ago
  • 4 min read

Updated: 18 hours ago

Why We Need a New Playbook for Mental Health

Mental health crises demand solutions and we find ourselves without a clear roadmap. 

I spoke with Prof. Gal Richter-Levin, a world-renowned expert in behavioral neuroscience at the University of Haifa, and this point echoed throughout our discussion. “We have no shortcuts,” he explained, as we explored the limitations of existing research methods and the need for innovation.


But what does that innovation look like? It requires embracing biological complexity, leveraging technological advances, and fostering meaningful global collaboration.


Why Biology is Non-Negotiable in Mental Health Research

One key theme of our conversation was the critical role of biology in understanding mental health. There’s a temptation in many discussions to sideline biological factors, as though they complicate rather than clarify the picture. To me, this feels fundamentally wrong—and Prof. Richter-Levin agreed.


“Biology isn’t optional—it’s the foundation. But it’s also incomplete,” he explained. “The problem isn’t studying biology; it’s overinterpreting what we learn from our models. That’s where we go wrong.”


“The problem isn’t studying biology; it’s overinterpreting what we learn from our models. That’s where we go wrong.”

This tension between biology’s necessity and its limitations makes finding reliable biomarkers for mental health particularly challenging, unlike in fields such as oncology. Personalized psychiatry faces significant barriers because the brain remains one of the most complex organs to study. The quest for biomarkers often feels like chasing a moving target.


Yet, biology doesn’t need to provide perfect answers. What we need is a framework—a foundation on which we can build and test ideas, layer by layer.


The Limitations of Animal Models and the Danger of Oversimplification

For decades, animal models have been at the core of neuroscience research, offering a window into understanding human disorders but  they are far from perfect. “Rodent models give us useful insights—but they also come with a price. A rat is not a human. We have to stop pretending it is.”


The reality is that while animal models allow for experiments that would be impossible or unethical in humans, they only provide part of the picture.

“The danger,” he said, “is when researchers present results as though they’ve studied the human brain. They haven’t. They’ve studied a limited, imperfect model—and that’s okay as long as we acknowledge it.”


“The danger,” he said, “is when researchers present results as though they’ve studied the human brain. They haven’t. They’ve studied a limited, imperfect model—and that’s okay as long as we acknowledge it.”

Unfortunately, this over-reliance on simplified conclusions has had serious consequences. Many pharmaceutical companies have stopped investing in mental health drug development because animal models have failed to deliver the breakthroughs they expected.

“The models failed to deliver because they promised too much,” Prof. Richter-Levin explained. “And as a result, companies stopped looking for new solutions.”


The Path Forward: Collaboration, Long-Term Investment, and Humility

Despite these challenges, there’s reason for optimism. As Prof. Richter-Levin and I discussed, other fields—such as oncology and HIV research—have faced similar roadblocks and overcome them through collaboration. When research efforts and funding were pooled across institutions and countries, breakthroughs followed.


This kind of collaboration is exactly what mental health research needs. Israel has the potential to serve as a “global petri dish,” bringing together research, technological innovation, and lessons learned from public health initiatives.


The role of emerging technologies, such as AI chatbots, neuromodulation, and brain organoids, is equally critical. These tools have the potential to address some of the gaps left by traditional research methods, but only if they are used responsibly. 

Prof. Richter-Levin was quick to point out the limitations of these technologies: “Organoids and human-derived cell models sound like the perfect solution, but they’re not a magic bullet,” he explained. “They’re an artifact of the lab environment. We’re not studying a human brain—we’re studying a piece of tissue that behaves in a certain way under artificial conditions.”


“They’re an artifact of the lab environment. We’re not studying a human brain—we’re studying a piece of tissue that behaves in a certain way under artificial conditions.”

Still, we agreed that technological advances, when combined with rigorous evidence generation, could open the door to new possibilities. The key is to approach these innovations with humility and patience. “There’s no holy grail,” Prof. Richter-Levin reminded me. “No single biomarker, no magic drug. But that doesn’t mean we stop looking. It means we invest in understanding the complexities and work together to tackle them.”


For policymakers, researchers, and philanthropists, this means shifting the focus from quick wins to long-term, sustained investment. As we’ve seen in cancer and HIV, breakthroughs come when we combine resources, share knowledge, and remain open to learning from failure.


Evidence generation plays a crucial role in this process—not just to prove that something works but to demonstrate that it works at scale, across different populations, and under real-world conditions. Without this, even the most promising solutions may fail to create lasting change.


Conclusion: Building a New Playbook

Mental health research is at a critical juncture. The old methods aren’t enough, and the solutions aren’t simple. But with the right combination of biological research, technological innovation, and global collaboration, we can begin building a new playbook—one that doesn’t promise perfection but does promise progress.


As I left my conversation with Prof. Gal Richter-Levin, I felt hopeful. Not because the challenges are any less daunting, but because the path forward is clearer: embrace complexity, acknowledge limitations, and work together to close the gaps. As he put it, “We may never find a single solution, but we’ll get a lot further when we stop pretending we already have one.”



Image of 2 women in a lab looking at a tablet.


Comments


bottom of page